Large-scale genomic studies have shown that half of epithelial ovarian cancers (EOCs) have alterations in genes regulating homologous recombination (HR) repair 1 . Loss of HR accounts for the genomic instability of EOCs and for their cellular hyper-dependence on alternative poly-ADP ribose polymerase (PARP)-mediated DNA repair mechanisms [2] [3] [4] [5] . Previous studies have implicated the DNA polymerase h (Polh also known as POLQ, encoded by POLQ) 6 in a pathway required for the repair of DNA double-strand breaks [7] [8] [9] , referred to as the error-prone microhomology-mediated end-joining (MMEJ) pathway [10] [11] [12] [13] . Whether Polh interacts with canonical DNA repair pathways to prevent genomic instability remains unknown. Here we report an inverse correlation between HR activity and Polh expression in EOCs. Knockdown of Polh in HR-proficient cells upregulates HR activity and RAD51 nucleofilament assembly, while knockdown of Polh in HR-deficient EOCs enhances cell death. Consistent with these results, genetic inactivation of an HR gene (Fancd2) and Polq in mice results in embryonic lethality. Moreover, Polh contains RAD51 binding motifs and it blocks RAD51-mediated recombination. Our results reveal a synthetic lethal relationship between the HR pathway and Polh-mediated repair in EOCs, and identify Polh as a novel druggable target for cancer therapy.
To examine changes in polymerase activity between tumours and normal tissues, we screened polymerase gene expression profiles in a large number of cancers (Supplementary Table 1 ). Gene set enrichment analysis (GSEA) revealed specific and recurrent overexpression of Polh in EOCs (Extended Data Fig. 1a-c) . Polh was upregulated in a gradedependent manner and its expression positively correlated with numerous mediators of HR (Extended Data Fig. 1d-j) . As Polh has been suggested to play a role in DNA repair [7] [8] [9] [10] , we investigated a potential role for Polh in HR repair.
To test the relationship between Polh expression and HR, we used a cell-based assay in human cells which measures the efficiency of recombination of two GFP alleles (DR-GFP assay) 14 . Knockdown of Polh with short interfering RNA (siRNA) (Extended Data Fig. 2a ) resulted in an increase in HR efficiency, similar to that observed by depleting the antirecombinases PARI or BLM 15, 16 . Depletion of Polh caused a significant increase in basal and radiation (IR)-induced RAD51 foci (Fig. 1a, b and Extended Data Fig. 2b-d) , and depletion of Polh in 293T cells conferred cellular hypersensitivity to mitomycin C (MMC) and an increase in MMC-induced chromosomal aberrations (Extended Data Fig. 2e, f) . These findings suggest that human Polh inhibits HR and participates in the maintenance of genome stability.
Given that Polh shares structural homology with coexpressed RAD51-binding ATPases (Extended Data Fig. 1k, l) , we hypothesized that Polh might regulate HR through an interaction with RAD51. RAD51 was detected in Flag-tagged Polh immunoprecipitates, and purified full-length Flag-Polh bound recombinant human RAD51 (Fig. 1c, d ). Pull-down assays with recombinant GST-RAD51 and in vitro translated Polh truncation mutants defined a region of Polh binding to RAD51 spanning amino acids 847-894 (Fig. 1e, f and Extended Data Fig. 2g, h ). Sequence homology of Polh with the RAD51 binding domain of C. elegans RFS-1 (ref. 17 ) identified a second binding region (Extended Data Fig. 2i ). Peptides arrays narrowed down the RAD51 binding activity of Polh to three distinct motifs ( Fig. 1g and Extended Data Fig. 2j ). Substitution arrays confirmed the interaction and highlighted the importance of the 847-894 Polh region as both necessary and sufficient for RAD51 binding (Extended Data Fig. 3a, b ). Together these results indicate that Polh is a RAD51-interacting protein that regulates HR.
In order to address the role of Polh in HR regulation, we assessed the ability of wild-type or mutant Polh to complement the siPolh-dependent increase in RAD51 foci. Full-length wild-type Polh fully reduced IR-induced RAD51 foci, unlike Polh mutated at ATPase catalytic residues (A-dead) or Polh lacking interaction with RAD51 (DRAD51) (Fig. 2a, b) . Expression of a Polh mutant lacking the polymerase domain (DPol1) was sufficient to decrease IR-induced RAD51 foci, suggesting that the N-terminal half of Polh is sufficient to disrupt RAD51 foci ( Fig. 2b and Extended Data Fig. 3c, d ). We next measured the ability of wildtype or mutant Polh to complement the siPolh-dependent increase in HR efficiency. Again, expression of full-length Polh or DPol1 decreased the recombination frequency when compared to cells expressing other Polh constructs, suggesting that the N-terminal half of Polh containing the RAD51 binding domain and the ATPase domain is needed to inhibit HR ( Fig. 2c and Extended Data Fig. 3e) .
A purified recombinant Polh fragment (DPol2) from insect cells exhibited low levels of basal ATPase activity, as previously reported 18 ( Fig. 2d , e). Polh ATPase activity was selectively stimulated by the addition of singlestranded DNA (ssDNA) or fork DNA ( Fig. 2e and Extended Data Fig. 4a ). Electrophoretic mobility gel shift assays (EMSA) showed specific binding of Polh to ssDNA ( Fig. 2f and Extended Data Fig. 4b ). We incubated DPol2 with ssDNA and measured RAD51-ssDNA nucleofilament assembly. Interestingly, RAD51-ssDNA assembly was reduced by DPol2 wildtype but not by A-dead or DRAD51, indicating that Polh negatively affects RAD51-ssDNA assembly through its RAD51 binding and ATPase activities ( Fig. 2g and Extended Data Fig. 4c-f) . Furthermore, Polh decreased the efficiency of D-loop formation, confirming that Polh is a negative regulator of HR ( Fig. 2h and Extended Data Fig. 4g-j) .
As Polh is upregulated in subgroups of cancers associated with HR deficiency ( Fig. 3a) and Polh activity shows specificity for replicative-stressmediated structures (ssDNA and fork DNA) (Fig. 2e, f) , we examined the cellular functions of Polh under replicative stress. Subcellular fractionation revealed that Polh is enriched in chromatin in response to ultraviolet (UV) light; and RAD51 binding by Polh was enhanced by UV exposure, suggesting that Polh regulates HR in cells under replicative stress (Extended Data Fig. 5a, b) . Polh-depleted cells were hypersensitive to cellular stress and DNA damage, along with an exacerbated checkpoint activation and increased cH2AX phosphorylation (Fig. 3b, c) . Furthermore, the cell cycle progression of Polh-depleted cells was impaired after DNA damage (Fig. 3d, e) . To determine the role of Polh in replication a b e f Polθ: 
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dynamics, single-molecule analyses were performed on extended DNA fibres 19 . Abnormalities in replication fork progression were observed in Polh-depleted cells (Fig. 3f, g and Extended Data Fig. 5c, d ). These results suggest that Polh maintains genomic stability at stalled or collapsed replication forks by promoting fork restart.
To examine the regulation of Polh, we quantified Polh expression by RT-qPCR. Polh was selectively upregulated in HR-deficient ovarian cancer cell lines. Complementation of BRCA1 or FANCD2-deficient cell lines with BRCA1 and FANCD2 cDNA respectively, restored normal HR function and reduced Polh expression to normal levels. Conversely, siRNA-mediated inhibition of HR genes increased Polh expression (Extended Data Fig. 5e, f) . Polh expression was significantly higher in subgroups of cancers with HR deficiency and a high genomic instability pattern 20 ( Fig. 3a and Extended Data Fig. 5g ). Patients with high Polh expression had a better response to platinum chemotherapy, a surrogate for HR deficiency, suggesting that Polh expression inversely correlates with HR activity and may be useful as a biomarker for platinium sensitivity (Extended Data Fig. 5h, i) . Together, these data indicate that increased Polh expression is driven by HR deficiency.
To assess the possible synthetic lethality between HR genes and Polh, we generated an HR-deficient ovarian tumour cell line, A2780-shFANCD2 cells (Extended Data Fig. 6a-c) . These cells, and the parental A2780 cells, were subjected to Polh depletion, and survival following exposure to cytotoxic drugs was measured. Polh depletion reduced the survival of HR-deficient cells exposed to inhibitors of PARP (PARPi), cisplatin (CDDP) or MMC (Extended Data Fig. 6d-f ). Polh inhibition impaired the survival of BRCA1-deficient tumours (MDA-MB-436) after PARPi treatment but had no effect on the complemented line (MDA-MB-436 1 BRCA1) (Fig. 4a) . Polh-depleted cells were hypersensitive to ATM inhibition, known to create an HR defect phenotype 21 . Chromosomal breakage, checkpoint activation, and cH2AX phosphorylation in response to MMC were exacerbated by Polh depletion (Fig. 4b and Extended Data Fig. 6g, h ). Furthermore, a whole-genome short hairpin RNA (shRNA) screen performed on HR-deficient (FANCA 2/2 ) fibroblasts showed that shRNAs targeting Polh impair cell survival in MMC (Extended Data Fig. 6i 
Polq
-/-embryos showed hypersensitivity to PARPi (Fig. 4c and Extended Data Fig. 7b-e) . These data suggest that loss of the HR and Polh repair pathways in vivo results in embryonic lethality. 
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As xenografts of tumours cells expressing shRNAs against both FANCD2 and Polh did not stably propagate in mice (Extended Data Fig. 7f ), we xenotransplanted A2780-shFANCD2 cells expressing either doxycycline-inducible Polh or scrambled (Scr) shRNA in athymic nude mice. Polh depletion significantly impaired tumour growth after PARPi treatment (Fig. 4d , e and Extended Data Fig. 7g, h ). Moreover, mice bearing Polh-depleted tumours had a survival advantage following PARPi treatment compared to control mice (Fig. 4f) . Polh-depleted HR-deficient tumour cells also exhibited decreased survival in in vivo dual-colour competition experiments (Extended Data Fig. 7i-l) . Collectively, these data confirm that HR-deficient tumours are hypersensitive to inhibition of Polh-mediated repair.
To understand which functions of Polh are required for resistance to DNA-damaging agents, we performed a series of complementation studies in HR-deficient cells. Expression of full-length Polh or DPol1, but not DRAD51, in HR-deficient Polh-depleted cells treated with PARPi or MMC was able to rescue toxicity, suggesting that the anti-recombinase activity of Polh maintains the genomic stability of HR-deficient cells (Fig. 4g , h and Extended Data Fig. 8a, b) . Moreover, the toxicity induced by loss of Polh in HR-deficient cells was rescued by depletion of RAD51 showing that, in the absence of Polh, RAD51 is toxic to HR-deficient cells (Fig. 4i) . These results suggest a role for Polh in limiting toxic HR events 23 (Extended Data Fig. 8c -f) and may explain why HR-deficient cells overexpress and depend on an anti-recombinase for survival.
High mutation rates have been observed in HR-deficient tumours 24 . Previous studies have shown that Polh is an error-prone polymerase 25, 26 that participates in alternative end-joining (alt-EJ) 10 . Therefore, we assessed the role of Polh in error-prone DNA repair in human cancer cells. Polh inhibition reduced alt-EJ efficiency in U2OS cells, similar to the reduction observed following depletion of PARP1, another critical factor in end-joining 27, 28 (Extended Data Fig. 9a ). Expression of full-length Polh, DRAD51, or A-dead, but not the DPol1 mutant, complemented the cells, suggesting that the polymerase domain of Polh is required for end-joining (Extended Data Fig. 9b ). GFP-tagged fulllength Polh formed foci after UV treatment in a PARP-dependent manner (Extended Data Fig. 9c ). Polh inhibition reduced the mutation frequency induced by UV light, and tumours with high Polh expression harboured more somatic point mutations than those with lower Polh levels (Extended Data Fig. 9d , e). These results suggest that Polh contributes to the mutational signature observed in some HR-deficient tumours 29 .
In human cancers, a deficiency in one DNA repair pathway can result in cellular hyper-dependence on a second compensatory DNA repair pathway 4 . Here we show that Polh is overexpressed in EOCs and other tumours with HR defects 30 . Wild-type Polh limits RAD51-ssDNA nucleofilament assembly (Extended Data Fig. 10a ) and promotes alt-EJ (Fig. 4j) . We demonstrate that HR-deficient tumours are hypersensitive to inhibition of Polh-mediated repair. Therefore, Polh appears to channel DNA repair by antagonizing HR and promoting PARP1-dependent error-prone repair (Extended Data Fig. 10b ). These results offer a potential new therapeutic target for cancers with inactivated HR. 
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METHODS
Bioinformatic analysis. Gene Set Enrichment Analysis algorithm (GSEA, http:// www.broadinstitute.org) was performed for the data sets summarized in Supplementary Table 1 . TransLesion Synthesis (TLS) and polymerase gene sets are described in Supplementary Table 3 . Row expression data were downloaded from Gene Expression Omnibus (GEO). Quantile normalizations were performed using the RMA routine through GenePattern. GSEA was run using GenePattern (http://www. broadinstitute.org) and corresponding P values were computed using 2,000 permutations. The DNA repair gene set used in Extended Data Fig. 1g has been determined according to a list of 151 DNA genes previously used 31 . GSEA analysis for 151 repair genes has been performed on the ovarian serous data sets (GSE14001, GSE14007, GSE18520, GSE16708, GSE10971). The list of 20 genes shown in Extended Data Fig. 1g represents the top 20 expressed gene in cancer samples (median of the 5 data sets). The waterfall plot in Extended Data Fig. 1h was generated as follows: the 20 genes defined in Extended Data Fig. 1g were used as a gene set; GSEA for indicated data sets was performed and the nominal P values were plotted. Supervised analysis of gene expression for GSE9891 was performed with respect to differential expression that differentiated the third of tumours with highest POLQ expression from the two-thirds with lowest POLQ levels. A list of the 200 most differentially expressed probe sets between the 2 groups (Supplementary Table 2 ) with false discovery rate ,0.05 was analysed for biological pathways (hypergeometrical test; http://www. broadinstitute.org). TCGA data sets were accessed through the public TCGA data portal (https://tcga-data.nci.nih.gov/tcga/). Fig. 3a reflects POLQ gene expression in the ovarian carcinoma data set GSE9891, uterine carcinoma TCGA and breast carcinoma TCGA. Normalization of POLQ expression values across data sets was performed using z-score transformation. POLQ expression values were subdivided in subgroups reflecting the stage of the disease (for GSE9891: grade 3 ovarian serous carcinoma, n 5 143 compared to type 1 (grade 1) ovarian cancers, n 5 20; for uterine: serous-like tumours, n 5 60 compared to the rest of the tumours, n 5 172; for breast: basal-like breast carcinoma, n 5 80 compared to the rest of the tumours, n 5 421). Progression-free survival curves were generated by the Kaplan-Meier method and differences between survival curves were assessed for statistical significance with the log-rank test. In the absence of a clinically defined cut-off point for POLQ expression levels, we divided patients into 2 groups: those with POLQ mRNA levels equal to or above the median (POLQ high group) and those with values below the median (POLQ low group). We then analysed the correlation of POLQ with outcome in each group. Patients with cyclin E1 (CCNE1) amplification (resistant to CDDP) were excluded from the analysis. For mutation count, we accessed data from tumours included in the TCGA data sets for which gene expression and whole-exome DNA sequencing was available. Data were accessed through the public TCGA data portal and the cBioPortal for Cancer Genomics (http://www.cbioportal.org). For each TCGA data set, non-synonymous mutation count was assessed in tumours with the highest POLQ expression (top 33%) and compared to tumours with low POLQ expression (the remaining 67%). In the uterine TCGA 20 , we curated all tumours except the ultra and hyper-mutated group (that is, POLE and MSI tumours). In the breast TCGA 32 , all tumours were analysed. In the ovarian TCGA 1 , we curated tumours harbouring molecular alterations (via mutation and epigenetic silencing) of the HR pathway. Plasmid construction. To facilitate subcloning, a silent mutation (A390A) was introduced into the POLQ gene sequence to remove the unique Xho1 cutting site. Full-length or truncated POLQ cDNA were PCR-amplified and subcloned into pcDNA3-N-Flag, pFastBac-C-Flag, pOZ-C-Flag-HA, or GFP-C1 vectors to generate the various constructs. Point mutations and loop deletions were introduced by QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) and confirmed by DNA sequencing. For Polh rescue experiments (Fig. 4g, h and Extended Data Fig. 3d, e) , POLQ cDNA constructs resistant to siPolh1 were generated into the pOZ-C-Flag-HA vector and the constructs were stably expressed in indicated cell line by retroviral transduction. The Polh ATPase catalytically-dead mutant (Adead) was generated by mutating the Walker A and B motifs (Walker A: K121A and Walker B: D216A, E217A). pOZ-C-Flag-HA Polh constructs were generated for retroviral transduction, and stable cells were selected using magnetic Dynabeads (Life Technologies) conjugated to the IL2R antibody (Millipore). SiRNA and shRNA sequence information. For siRNA-mediated knockdown, the following target sequences were used: POLQ (Qiagen POLQ_1 used as siPolh1 and Qiagen POLQ_6 used as siPolh2); BRCA1 (Qiagen BRCA1_13); PARP1 (Qiagen PARP1_6); REV1 (59-CAGCGCAUCUGUGCCAAAGAA-TT-39); BRCA2 (59-G AAGAAUGCAGGUUUAAUATT-39); BLM (59-AUCAGCUAGAGGCGAUCA ATT-39); FANCD2 (59-GGAGAUUGAUGGUCUACUATT-39) and PARI (59-A GGACACAUGUAAAGGGAUUGUCUATT-39). AllStars negative control siRNA (Qiagen) served as the negative control. ShRNAs targeting human FANCD2 was previously generated in the pTRIP/DU3-MND-GFP vector 33 . ShRNAs targeting human POLQ (CGGGCCTCTTTAGATATAAAT), human BRCA2 (AAGAAGA ATGCAGGTTTAATA) or control (Scr, scramble) were generated in the pLKO-1 vector. POLQ (V2THS_198349) and non-silencing TRIPZ-RFP doxycyclineinducible shRNA were purchased from Open Biosystems. All shRNAs were transduced using lentivirus. Immunoblot analysis, fractionation and pull-down assays. Cells were lysed with 1% NP-40 lysis buffer (1% NP-40, 300 mM NaCl, 0.1 mM EDTA, 50 mM Tris (pH 7.5)) supplemented with protease inhibitor cocktail (Roche), resolved by NuPAGE (Invitrogen) gels, and transferred onto nitrocellulose membrane, followed by detection using the LAS-4000 Imaging system (GE Healthcare Life Sciences). For immunoprecipitation, cells were lysed with 300 mM NaCl lysis buffer, and the lysates were diluted to 150 mM NaCl before immunoprecipitation. Lysates were incubated with anti-Flag agarose resin (Sigma) followed by washes with 150 mM NaCl buffer. In vitro transcription and translation reactions were carried out using the TNT T7 Quick Coupled Transcription-Translation System (Promega). For cellular fractionation, cells were incubated with low-salt permeabilization buffer (10 mM Tris (pH 7.3), 10 mM KCl, 1.5 mM MgCl 2 ) with protease inhibitor on ice for 20 min. Following centrifugation, nuclei were resuspended in 0.2 M HCl and the soluble fraction was neutralized with 1 M Tris-HCl (pH 8.0). Nuclei were lysed in 150 mM NaCl and following centrifugation, the chromatin pellet was digested by micrococcal nuclease (Roche) for 5 min at room temperature. Recombinant GST-RAD51 and GST-PCNA fusion protein were expressed in BL21 strain and purified using glutathione-Sepharose beads (GE Healthcare) as previously described 15 . Beads with equal amount of GST or GST-RAD51 were incubated with in vitro translated Flagtagged Polh variants in 150 mM NaCl lysis buffer. Antibodies and chemicals. Antibodies used in this study included: anti-PCNA (PC-10), anti-FANCD2 (FI-17), anti-RAD51 (H-92), anti-GST (B14), and histone H3 (FL-136) and anti-vinculin (H-10) (Santa Cruz); anti-Flag (M2) (Sigma); antipS317CHK1 (2344), anti-pT68CHK2 (2661) (Cell signalling); anti-pS824KAP-1 (A300-767A) (Bethyl); anti-pS317cH2AX (05636) (Millipore); anti-pS15p53 (ab1431) and anti-Polh (ab80906) (abcam); anti-BrdU (555627) (BD Pharmingen). Mitomycin C (MMC), cis-diamminedichloroplatinum(II) (cisplatin, CDDP), and hydroxyurea (HU) were purchased from Sigma. The PARPi rucaparib (AG-014699) was purchased from Selleckchem and ABT-888 from AbbVie. Rucaparib was used for all in vitro assays and ABT-888 was used for all in vivo experiments. Chromosomal breakage analysis. 293T and VU 423 cells were twice-transfected with siRNAs for 48 h and incubated for 48 h with or without the indicated concentrations of MMC. For complementation studies on 293T shFANCD2, POLQ cDNA constructs were transfected 24 h after the first siRNA transfection. Cells were exposed for 2 h to 100 ng ml 21 of colcemid and treated with a hypotonic solution (0.075 M KCl) for 20 min and fixed with 3:1 methanol/acetic acid. Slides were stained with Wright's stain and 50 metaphase spreads were scored for aberrations. The relative number of chromosomal breaks was calculated relative to control cells (si Scr). Radial figures were excluded from the analysis for clarity in Fig. 4b . Reporter assays and immunofluorescence. HR and alt-EJ efficiency was measured using the DR-GFP (HR efficiency) and the alt-EJ reporter assay, performed as previously described 14, 27, 34 . Briefly, 48 h before transfection of SceI cDNA, U20S-DR-GFP cells were transfected with the indicated siRNA or PARPi (1 mM). The HR activity was determined by FACS quantification of viable GFP-positive cells 96 h after SceI was transfected. For RAD51 immunofluorescence experiments, cells were transfected with indicated siRNA 48 h before treatment with HU (2 mM) or IR (10 Gy). For complementation studies, Polh cDNA constructs were either transfected 24 h after siRNA transfection (Fig. 2b, c and Extended Data Fig. 9b ) or stably expressed in the indicated cell line (Extended Data Fig. 3d , e). 6 h after HU or IR treatment, cells were fixed with 4% paraformaldehyde for 10 min at room temperature, followed by extraction with 0.3% Triton X-100 for 10 min on ice. Antibody staining was performed at room temperature for 1 h. For quantification of RAD51 foci in BrdU positive cells, cells were transfected with indicated siRNA 48 h before treatment with IR (10 Gy). Then 2 h after IR treatment, cells were treated with BrdU pulse (10 mM) for 2 h and subsequently fixed with 4% paraformaldehyde and stained for RAD51 as described above. Cells were then fixed in ethanol (4 uC, overnight), treated with 1.5 M HCl for 30 min and stained for BrdU antibody. The relative number of cells with more than 10 RAD51 foci was calculated relative to control cells (si Scr). Statistical differences between cells transfected with siRNAs (si Polh1, si Polh2, si BRCA2, si PARI or si BLM relative to control (si Scr) were assessed. For GFP fluorescence, cells were grown on coverslips, treated with UV (24 h after GFPPolh transfection; 20 J m
22
), fixed with 4% paraformaldehyde for 10 min at 25 uC 4 h after the UV treatment, washed three times with PBS and mounted with DAPIcontaining mounting medium (Vector Laboratories). When indicated, cells were treated with PARPi (1 mM) 24 h before GFP-Polh transfection. Images were captured using a Zeiss AX10 fluorescence microscope and AxioVision software. Cells with GFP foci were quantified by counting number of cells with more than five foci. At least 150 cells were counted for each sample. Cell survival assays. For assessing cellular cytotoxicity, cells were seeded into 96-well plates at a density of 1,000 cells per well. Cytotoxic drugs were serially diluted LETTER RESEARCH in media and added to the wells. At 72 h, CellTiter-Glo reagent (Promega) was added to the wells and the plates were scanned using a luminescence microplate reader. Survival at each drug concentration was plotted as a percentage of the survival in drug-free media. Each data point on the graph represents the average of three measurements, and the error bars represent the standard deviation. For clonogenic survival, 1,000 cells per well were seeded into 6-well plates and treated with cytotoxic drugs the next day. For MMC and PARPi, cells were treated continuously with indicated drug concentrations. For CDDP, cells were treated for 24 h and cultured for 14 days in drug-free media. Colony formation was scored 14 days after treatment using 0.5% (w/v) crystal violet in methanol. Survival curves were expressed as a percentage 6 s.e.m. over three independent experiments of colonies formed relative to the DMSO-treated control. Cell cycle analysis. A2780 cells expressing Scr or Polh shRNA were synchronized by a double thymidine block (Sigma) and subsequently exposed to MMC (1 mg ml 21 for 2 h), IR (10 Gy) or HU (2 mM, overnight). At the indicated time points following drug release, cells were fixed in chilled 70% ethanol, stored overnight at 220 uC, washed with PBS, and resuspended in propidium iodide. A fraction of those cells was analysed by immunoblotting for DNA damage response proteins. The immunoblot analysis of cH2AX shows staining after 0, 24, 48 and 72 h of HU treatment. For proliferation experiments, cells were incubated with 5-ethynyl-29-deoxyuridine (EdU) (10 mM) for 1 h at each time point after MMC exposure (1 mg ml 21 for 2 h). Cells were washed and resuspended in culture medium for 2 h before be analysed by flow cytometry. Edu staining was performed using the Click-iT EdU kit (Life Technologies). DNA fibre analysis. A2780 cells expressing Scr or Polh shRNA were incubated with 25 mM chlorodeoxyuridine (CldU) (Sigma, C6891) for 20 min. Cells were then treated with 2 mM hydroxyurea (HU) for 2 h and incubated in 250 mM iododeoxyuridine (ldU) (Sigma, I7125) for 25 min after washout of the drug. Spreading of DNA fibres on glass slides was done as previously reported 19 . Glass slides were then washed in distilled water and in 2.5 M HCl for 80 min followed by three washes in PBS. The slides were incubated for 1 h in blocking buffer (PBS with 1% BSA and 0.1% NP-40) and then for 2 h in rat anti-BrdU antibody (1:250, Abcam, ab6326). After washing with blocking buffer, the slides were incubated for 2 h in goat anti-rat Alexa 488 antibody (1:1,000, Life Technologies, A-11006). The slides were then washed with PBS and 0.1% NP-40 and then incubated for 2 h with mouse anti-BrdU antibody diluted in blocking buffer (1:100, BD Biosciences, 347580). Following an additional wash with PBS and 0.1% NP-40, the fibres were stained for 2 h with chicken anti-mouse Alexa 594 (1:1000, Life Technologies, A-21201). At least 150 fibres were counted per condition. Pictures were taken with an Olympus confocal microscope and the fibres were analysed by ImageJ software. The number of stalled or collapsed forks were measured by DNA fibres that had incorporated only CIdU. Stalled or collapsed forks counted in Polh-depleted cells is expressed as fold-change after HU treatment relative to the fold-change observed in control cells, which was arbitrarily set to 1. SupF mutagenesis assay. 293T cells twice-transfected with siRNAs for 48 h were then transfected with undamaged or damaged (UVC, 1,000 J m
) pSP189 plasmids using GeneJuice (Novagen). After 48 h, plasmid DNA was isolated with a miniprep kit (Promega) and digested with DpnI. After ethanol precipitation, extracted plasmids were transformed into the b-galactosidase2MBM7070 indicator strain through electroporation (GenePulsor X Cell; Bio-Rad) and plated onto LB plates containing 1 mM IPTG, 100 mg ml 21 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside and 100 mg ml 21 ampicillin. White and blue colonies were scored using ImageJ software, and the mutation frequency was calculated as the ratio of white (mutant) to total (white plus blue) colonies. POLQ gene expression. RNA samples extracted using the TRIzol reagent (Invitrogen) were reverse transcribed using the Transcriptor Reverse Transcriptaze kit (Roche) and oligo dT primers. The resulting cDNA was use to analysed POLQ expression by RT-qPCR using with QuantiTect SYBRGreen (Qiagen), in an iCycler machine (Bio-Rad). POLQ gene expression values were normalized to expression of the housekeeping gene GAPDH, using the DCt method and are shown on a log 2 scale. The primers used for POLQ are as follows: POLQ primer 1 (forward: 59-TATCTG CTGGAACTTTTGCTGA-39; reverse: 59-CTCACACCATTTCTTTGATGGA-39); POLQ primer 2 (forward: 59-CTACAAGTGAAGGGAGATGAGG-39; reverse: 59-TCAGAGGGTTTCACCAATCC-39). Polh purification from insect SF9 cells. A Polh fragment (DPol2) containing the ATPase domain with a RAD51 binding site (amino acids 1 to 1,000) was cloned into pFastBac-C-Flag and purified from baculovirus-infected SF9 insect cells as previously described 35 . Briefly, SF9 cells were seeded in 15-cm dishes at 80-90% confluency and infected with baculovirus. Three days post-infection, cells were collected and lysed in 500 mM NaCl lysis buffer (500 mM NaCl, 0.01% NP-40, 0.2 mM EDTA, 20% glycerol, 1 mM DTT, 0.2 mM PMSF, 20 mM Tris (pH 7.6)) supplemented with Halt protease inhibitor cocktail (Thermo Scientific) and calpain I inhibitor (Roche) and the protein was eluted in lysis buffer supplemented with 0.2 mg ml 21 of Flag peptide (Sigma). The protein was concentrated in lysis buffer using 10 kDa centrifugal filters (Amicon). The protein was quantified by comparing its staining intensity (Coomassie-R250) with that of BSA standards in a 7% Tris-glycine SDS-PAGE gel. Purified protein was flash-frozen in small aliquots in liquid nitrogen and stored at 280 uC. Radiometric ATPase assay. Each 10 ml reaction consisted of 200 nM ATP, reaction buffer (20 mM Tris-HCl (pH 7.6), 5 mM MgCl 2 , 0.05 mg ml 21 BSA, 1 mM DTT), and 5 mCi of [c-32 P]ATP. For corresponding reactions, ssDNA, dsDNA, and forked DNA were added to the reaction in excess at a final concentration of 600 nM. Once all of the non-enzymatic reagents were combined, recombinant Polh was added to start the ATPase reaction. After incubation for 90 min at room temperature, stop buffer (125 mM EDTA (pH 8.0)) was added and approximately ,0.05 mCi was spotted onto PEI-coated thin-layer chromatography (TLC) plates (Sigma). Unhydrolyzed [c- 32 P]ATP was separated from the released inorganic phosphate [ 32 P i ] with 1 M acetic acid, 0.25 M lithium chloride as the mobile phase. TLC plates were exposed to a phosphor screen and imaged with the BioRad Imager PMC. ssDNA, dsDNA, and forked DNA were generated as previously described 35 . To remove any contaminating ssDNA, dsDNA and forked DNA were gel purified after annealing. Spots corresponding to [c- 32 P]ATP and the released inorganic phosphate [ 32 P i ] were quantified (in units of pixel intensity) and the fraction of ATP hydrolysed calculated for each Polh concentration. Electrophoretic mobility gel shift assay (EMSA). Binding of Polh to ssDNA was assessed using EMSA. 60-mer single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA) oligonucleotides (5 nM) were incubated with increasing amount of Polh (0, 5, 10, 50, or 100 nM) in 10 ml of binding buffer (20 mM HEPES-K 1 , (pH 7.6), 5 mM magnesium acetate, 0.1 mg ml 21 BSA, 5% glycerol, 1 mM DTT, 0.2 mM EDTA, and 0.01% NP-40) for 1 h on ice. Polh protein was added at a tenfold dilution so that the final salt concentration was approximately 50 mM NaCl. The ssDNA probes were 59 fluorescently labelled with IRDye-700 (IDT). After incubation, the samples were analysed on a 5% native polyacrylamide/0.5X TBE gel at 4 uC. A fluorescent imager (Li-Cor) was used to visualize the samples in the gel. RAD51 purification. Human GST-RAD51 was purified from bacteria as described 36 . Xenopus Rad51 (xRad51) was purified as follows. N-terminally His-tagged SUMORad51 was expressed in BL21 pLysS cells. Three hours after induction with 1 mM IPTG, cells were collected and resuspended in buffer A (50 mM Tris-Cl (pH 7.5), 350 mM NaCl, 25% sucrose, 5 mM b-mercaptoethanol, 1 mM PMSF and 10 mM imidazole). Cells were lysed by supplementation with Triton X-100 (0.2% final concentration), three freeze-thaw cycles and sonication (20 pulses at 40% efficiency). The soluble fraction was separated by centrifugation and incubated with 2 ml of Ni-NTA resin (Qiagen) for 1 h at 4 uC. After washing the resin with 100 ml of wash buffer (buffer A supplemented with 1 M NaCl, final concentration), the salt concentration was brought down to 350 mM. His-SUMO-Rad51 was eluted with a linear gradient of imidazole from 10-300 mM in buffer A. Eluted fractions were analysed by SDS-PAGE. His-SUMO-Rad51 containing fractions were pooled and supplemented with Ulp1 protease to cleave the His-SUMO tag and dialysed overnight into buffer B (50 mM Tris-Cl (pH 7.5), 350 mM NaCl, 25% sucrose, 10% glycerol, 5 mM b-mercaptoethanol, 10 mM imidazole and 0.05% Triton X-100). The dialysed fraction was incubated with Ni-NTA resin for 1 h at 4 uC and the Rad51 containing flow-through fraction was collected and dialysed overnight into buffer C (100 mM potassium phosphate (pH 6.8), 150 mM NaCl, 10% glycerol, 0.5 mM DTT and 0.01% Triton-X). Rad51 was further purified by hydroxyapatite (Bio-Rad) chromatography. After washing with ten column volumes of buffer C, Rad51 was eluted with a linear gradient of potassium phosphate (pH 6.8) from 100-800 mM. Rad51 containing fractions were analysed by SDS-PAGE and dialysed into storage buffer (20 mM HEPES-KOH (pH 7.4), 150 mM NaCl, 10% glycerol, 0.5 mM DTT). Purified protein was flash-frozen in small aliquots in liquid nitrogen and stored at 280 uC. D-loop assay. D-loop formation assays were performed using xRad51 and conducted as previously described 37 . Briefly, nucleofilaments were first formed by incubating RAD51 (1 mM) with end-labelled 90-mer ssDNA (3 mM nt) at 37 uC for 10 min in reaction buffer containing 20 mM HEPES-KOH (pH 7.4), 1 mM ATP, 1 mM MgCl 2 , 1 mM DTT, BSA (100 mg ml 21 ), 20 mM phosphocreatine and creatine phosphokinase (20 mg ml
21
). After the 10 min incubation, increasing amounts of Polh (0, 0.1, 0.5, or 1.0 mM) and RPA (200nM) were added and incubated for an additional 15 min at 37 uC. The reaction was then supplemented with 1 mM CaCl 2 followed by further incubation at 37 uC for 15 min. D-loop formation was initiated by the addition of supercoiled dsDNA (pBS-KS (2), 79 mM bp) and incubation at 37 uC for 15 min. D-loops were analysed by electrophoresis on a 0.9% agarose gel after deproteinization. Gel was dried and exposed to a PhosphoImager (GE Healthcare) screen for quantification. Substitution peptide arrays and RAD51-ssDNA filament experiments. Substitution peptide arrays were performed as previously described 17 . RAD51 displacement assays were performed as follows. Binding reactions (10 ml) contained 59-32 P-end-labelled
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DNA substrates (0.5 ng of 60 mer ssDNA) and various amounts of human RAD51 and/or Polh in binding buffer (40 mM Tris-HCl (pH 7.5), 50 mM NaCl, 10 mM KCl, 2 mM DTT, 5 mM ATP, 5 mM MgCl2, 1 mM DTT, 100 mg ml 21 BSA) were conducted at room temperature. After 5 min incubation with Polh and a further 5 min incubation with RAD51 or vice versa, an equimolar amount of cold DNA substrate was added to the reaction. Products were then analysed by electrophoresis through 10% PAGE (200 V for 40 min in 0.53 Tris-borate-EDTA buffer) and visualized by autoradiography. Interbreeding of the Fancd2 and Polq mice. For the characterization of Fancd2/ Polq conditional knockouts, we crossed C57BL/6J mice (Jackson Laboratory Polq 1/2 mice. These double heterozygous mice were then interbred, and the offspring from these mating pairs were genotyped using PCR primers for Fancd2 and Polq. A statistical comparison of the observed with the predicted genotypes was performed using a two-sided Fisher's exact test. Primary MEFs were generated from E13.5 to E15 embryos and cultured in RPMI supplemented with 15% fetal bovine serum and 1% penicillin-streptomycin. All data generated in the study were extracted from experiments performed on primary MEFs from passage 1 to passage 4. The primers used for mice genotyping are as follows: Fancd2 PCR primers OST2cF (59-CATGCATATAGGAACCCGA AGG-39), OST2aR (59-CAGGACCTTTGGAGAAGCAG-39) and LTR2bF (59-G GCGTTACTTAAGCTAGCTTG-39); Polq PCR primers IMR5973 (59-TGCAGTG TACAGATGTTACTTTT-39), IMR 5974 (59-TGGAGGTAGCATTTCTTCTC-39), IMR 5975 (59-TCACTAGGTTGGGGTTCTC-39) and IMR 5976 (59-CATCAGA AGCTGACTCTAGAG-39). Specific PCR conditions are available upon request. Studies of xenograft-bearing CrTac:NCr-Foxn1nu mice. The Animal Resource Facility at The Dana-Farber Cancer Institute approved all housing situations, treatments and experiments using mice. No more than five mice were housed per airfiltered cage with ad libitum access to standard diet and water, and were maintained in a temperature-and light-controlled animal facility under pathogen-free conditions. All mice described in this text were drug and procedure naive before the start of the experiments. For every xenograft study, we subcutaneously implanted approximately 1.0 3 10 6 A2780 cells (1:1 in Matrigel Matrix, BD Biosciences) into both flanks of 6-8-week-old female CrTac:NCr-Foxn1nu mice (Taconic). Doxycycline (Sigma) was added to the food (625 p.p.m.) and bi-weekly (Tuesday and Friday) to the water (200 mg ml
21
) for mice bearing tumours that reached 100-200 mm 3 . Roughly one week (5-6 days) after the addition of doxycycline to the diet, mice were randomized to twice daily treatment schedules with vehicle (0.9% NaCl) or PARPi (ABT-888; 50 mg per kg body weight) by oral gavage administration for the indicated number of weeks. Overall survival was determined using KaplanMeier analyses performed with log-rank tests to assess differences in median survival for each shRNA condition (shScr or shPolh) and each treatment condition (vehicle or PARPi) (GraphPad Prism 6 Software). For competition assays, A2780 cells expressing FANCD2-GFP shRNA (GFP positive cells) or a combination of FANCD2-GFP shRNA with (doxycycline inducible) Scr-RFP or Polh-RFP shRNA (GFP-RFP positive cells) were mixed at an equal ratio of GFP to GFP-RFP positive cells, and thereafter injected into nude mice given doxycycline-containing diets and treated with either vehicle or PARPi or CDDP. For competition assays, mice received identical doxycycline and PARPi drug treatment. For the cisplatin competition assay, mice were randomized into semi-weekly treatment regimens with vehicle (0.9% NaCl) or CDDP (5 mg per kg body weight) by intraperitoneal injection. After three to four weeks of treatment, mice were euthanized and tumours were grown in vitro, in the presence of doxycycline (2 mg ml 21 for 4 days). The relative ratio of GFP to GFP-RFP positive cells was determined by FACS analysis. Tumour volumes were calculated bi-weekly using caliper measurements (length 3 width ) which was arbitrarily set to 1. Mice were unbiasedly assigned into different treatment groups. Drug treatment and outcome assessment was performed in a blinded manner. Mice were monitored every day and euthanized by CO 2 inhalation when tumour size ($ 2 cm), tumour status (necrosis/ ulceration) or body weight loss ($ 20%) reached ethical endpoint, according to the rules of the Animal Resource Facility at The Dana-Farber Cancer Institute. Immunohistochemical staining. We stained formalin-fixed paraffin-embedded sections of harvested xenografts with antibodies specific for cH2AX (pSer139) (Upstate Biotechnology) and Ki67 (Dako). At least two xenografts were scored for each treatment. Tumours were collected 3 weeks after treatment. At least five 40 3 fields were scored. The mean 6 s.e.m. percentage of positive cells from five images in each treatment group was calculated. Statistical analysis. Unless stated otherwise, all data are represented as mean 6 s.e.m. over at least three independent experiments, and significance was calculated using the Student's t-test. Asterisks indicate statistically significant (*P , 0.05; **P , 10
22
; ***P , 10
23
) values. All the in vivo experiments were run with at least 6 tumours from 6 mice for each condition. No statistical methods were used to predetermine sample size.
Extended Data Figure 1 | POLQ is highly expressed in epithelial ovarian cancers (EOCs) and POLQ expression correlates with expression of HR genes. a, b, Gene set enrichment analysis (GSEA) for expression of TransLesion Synthesis (TLS) (a) and polymerase (b) genes between primary cancers and control samples in 28 independent data sets from 19 different cancers types. Enrichment values (represented as a single dot for each gene in a defined data set) were determined using the rank metric score to compare expression values between cancers and control samples. Dots above the dashed line reflect enrichment in cancer samples, whereas dots below the dashed line show gene expression enriched in control samples. Data sets were ranked based on the amplitude of the rank metric score and plotted as shown. c, POLQ gene expression in 40 independent data sets from 19 different cancer types. For each data set, POLQ values were expressed as fold-change differences relative to the mean expression in control samples, which was arbitrarily set to 1. d, POLQ expression correlates with tumour grade and MKi67 gene expression in the ovarian TCGA (n 5 494 patients with ovarian carcinoma (grade 1, n 5 5; grade 2, n 5 61; grade 3, n 5 428) and control samples, n 5 8). e, POLQ expression correlates with tumour grade MKi67 gene expression in the ovarian data set GSE9891 (n 5 251 patients with ovarian serous and endometrious carcinoma for which grade status was available (grade 1, n 5 20; grade 2, n 5 88; grade 3, n 5 143)). Statistical correlation was assessed using the Pearson test (for d: r 5 0.65, P , 10
; for e: r 5 0.77, P , 10
). f, Top-ranked biological pathways differentially expressed between samples expressing high levels of POLQ (high POLQ, first 33%, n 5 95) relative to samples with low POLQ expression (low POLQ, 67%, n 5 190) on the ovarian data set GSE9891 (n 5 285 patients with ovarian carcinoma). Significance values were determined by the hypergeometrical test using the 200 most differentially expressed probe sets between the 2 groups (high POLQ and low POLQ). g, GSEA for expression of DNA repair genes between primary cancers and control samples in 5 independent ovarian cancer data sets. A representative heat map showing differential gene expression between ovarian cancers and controls is shown from GSE14407. For each data set, DNA repair genes were ranked based on the metric score reflecting their enrichment in cancer samples. The top 20 DNA repair genes primarily expressed in cancer samples compared to control samples is shown on the right. h, GSEA for the top 20 DNA repair genes defined in g between primary cancers and control samples in 40 independent cancer data sets. The nominal P value was used as a measure of the expression enrichment in cancer samples and represented as a waterfall plot. When the gene set expression was enriched in control samples, the P value was arbitrarily set to 1. i, POLQ expression correlates with RAD51 and FANCD2 gene expression in 285 samples from the ovarian data set GSE9891. Statistical correlation was assessed using the Pearson test (r 5 0.71, P , 10
). j, Top 10 genes that most closely correlated with POLQ expression (gene neighbours analysis) for 1,046 cell lines from the CCLE collection. DNA repair activity for these genes is indicated in the table. Increased HR gene expression is known to positively correlate with improved response to platinum based chemotherapy (a surrogate of HR deficiency) and thus can be predictive of decreased HR activity 31, 38 . Conceptually, a state of HR deficiency may lead to compensatory increased expression of other HR genes. k, Top-ranked Gene Ontology (GO) terms for the molecular functions encoded by the top 20 DNA repair genes defined in Extended Data Fig. 1g . l, Schematic representation of Polh domain structure with the helicases (BLM, RECQL4, RAD54B and RAD54L) that co-expressed with Polh (from Extended Data Fig. 1g ). Fig. 2g ) were subjected to UV treatment. Cells were collected at indicated time points after UV treatment and IPs were performed on nuclear and chromatin fractions. b, HeLa cells stably integrated with DPol1 were treated with UV and collected at the indicated time points following UV exposure. Polh and RAD51 co-precipitation is enhanced by UV treatment. c, Quantification of DNA fibre lengths isolated from wild-type or Polq 2/2 MEFs. d, Quantification of DNA fibre lengths isolated from wild-type or Polq 2/2 MEFs transfected with either EV or Polh cDNA constructs. e, POLQ gene expression was analysed by RT-qPCR in HR-deficient ovarian cancer cell lines (PEO-1 and UWB1-289) compared with other ovarian cancer cell lines, HeLa (cervical cancer) cells and 293T (transformed human embryonic kidney) cells. Expression was normalized using GAPDH gene as a reference.
POLQ expression values are displayed as fold-change relative to the mean expression in HR-proficient control cells, which was arbitrarily set to 1. f, POLQ gene expression analysis (RT-qPCR) in 293T cells transfected with siRNA targeting FANCD2, BRCA1 or BRCA2 (left panel) and in corrected PD20 cells (PD20 1 FANCD2) relative to FANCD2-deficient cells (PD20) (right panel). Expression was normalized using GAPDH gene as a reference. POLQ expression values are presented as fold-change relative to the mean expression in control cells, which was arbitrarily set to 1. g, POLQ gene expression in 5 data sets of serous epithelial ovarian carcinoma (frequently associated with an HR deficiency) and 1 data set of clear cell ovarian carcinoma (subgroup not associated with HR alterations). For each data set, POLQ expression values are displayed as fold-change differences relative to the mean expression in control samples, which was arbitrarily set to 1. h, Progression-free survival (PFS) after first line platinum chemotherapy for patients with ovarian carcinoma (ovarian carcinoma TCGA). Statistical significance was assessed by the log-rank test (P , 10
22
). i, Effect of Polh expression levels and HR status on tumour senstivity to cisplatin or PARPi. NA, not applicable. Box plots in c, d, and g show twenty-fifth to seventy-fifth percentiles, with lines indicating the median, and whiskers indicating the smallest and largest values. Data in e and f show mean 6 s.e.m. 
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Extended Data Figure 7 | HR and Polh repair pathways are
Polq
-/-offspring generated in the study. The offspring presented congenital malformations (that is, eye defects) together with reduced size and body weight. The arrow indicates absence of the right eye. c, Genotypes frequencies of E13.5 to E15 embryos (13.5 to 15 days post coitum) from interbred Fancd2 Each group represents n $ 5 tumours from n $ 5 mice. g, Ki67 and cH2AX quantification in tumours treated with either vehicle or PARPi. h, Representative Ki67 and cH2AX staining of A2780-shFANCD2 xenografts expressing sh Scr or sh Polh in athymic nude mice, treated with either vehicle or PARPi. Scale bars, 100 mM. i, In vivo competition assay design. j, Tumour chimaerism post-xenotransplantation for indicated conditions. k, Representative flow cytometry analysis of tumours before xenotransplantation (post-FACS sorting) or after xenotransplantation (posttransplant, PARPi). The percentage of GFP-RFP positive cells is indicated. l, Tumour chimaerism post-xenotransplantation for indicated conditions. For data in j and l, each circle represents data from one tumour and each group represents n $ 7 tumours from n $ 6 mice. Brackets show mean 6 s.e.m. Data in e-g show mean 6 s.e.m. For f each group represents n $ 6 tumours from n $ 6 mice. ) were collected at indicated time points after UV treatment and immunoblotting performed on the cytoplasmic, nuclear and chromatin fractions. f, RAD51 recruitment to chromatin in VU 423 cells (BRCA2 2/2 ) transfected with indicated siRNA. Histone H3 was used as a control for chromatin fractionation. All data show mean 6 s.e.m.
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